3,452 Shares in Waters Corporation $WAT Purchased by Folger Nolan Fleming Douglas Capital Management Inc.

Folger Nolan Fleming Douglas Capital Management Inc. purchased a new stake in shares of Waters Corporation (NYSE:WAT) in the 1st quarter, HoldingsChannel.com reports. The firm purchased 3,452 shares of the medical instruments supplier’s stock, valued at approximately $1,028,000.

A number of other large investors also recently bought and sold shares of WAT. Brighton Jones LLC boosted its position in Waters by 112.9% in the 4th quarter. Brighton Jones LLC now owns 1,269 shares of the medical instruments supplier’s stock worth $471,000 after purchasing an additional 673 shares in the last quarter. Integrated Wealth Concepts LLC lifted its stake in shares of Waters by 2.9% in the 1st quarter. Integrated Wealth Concepts LLC now owns 1,048 shares of the medical instruments supplier’s stock valued at $386,000 after purchasing an additional 30 shares during the period. Goldman Sachs Group Inc. lifted its stake in shares of Waters by 3.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 200,051 shares of the medical instruments supplier’s stock valued at $73,733,000 after purchasing an additional 6,976 shares during the period. Empowered Funds LLC boosted its holdings in Waters by 16.6% during the first quarter. Empowered Funds LLC now owns 1,126 shares of the medical instruments supplier’s stock worth $415,000 after buying an additional 160 shares in the last quarter. Finally, Sivia Capital Partners LLC purchased a new stake in Waters during the second quarter worth $232,000. 94.01% of the stock is owned by institutional investors and hedge funds.

Waters Stock Performance

Shares of NYSE:WAT opened at $369.65 on Tuesday. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.79 and a quick ratio of 1.13. Waters Corporation has a 1 year low of $275.05 and a 1 year high of $414.15. The firm has a market capitalization of $36.30 billion, a PE ratio of 46.97, a P/E/G ratio of 2.26 and a beta of 1.21. The business’s 50 day moving average price is $347.97 and its 200-day moving average price is $347.09.

Waters (NYSE:WAT) last posted its quarterly earnings data on Tuesday, May 5th. The medical instruments supplier reported $2.70 EPS for the quarter, beating the consensus estimate of $2.31 by $0.39. The firm had revenue of $1.27 billion during the quarter, compared to the consensus estimate of $1.20 billion. Waters had a return on equity of 15.60% and a net margin of 11.91%.The firm’s revenue was up 91.4% compared to the same quarter last year. During the same period in the prior year, the company earned $2.25 EPS. Waters has set its Q2 2026 guidance at 2.950-3.050 EPS and its FY 2026 guidance at 14.400-14.600 EPS. As a group, equities research analysts expect that Waters Corporation will post 14.51 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on WAT shares. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Waters in a report on Monday, April 20th. Robert W. Baird set a $387.00 target price on shares of Waters in a research note on Wednesday, May 6th. TD Cowen raised their target price on Waters from $345.00 to $385.00 and gave the company a “hold” rating in a research report on Wednesday, May 6th. Deutsche Bank Aktiengesellschaft restated a “hold” rating and issued a $350.00 price objective on shares of Waters in a research report on Thursday, May 7th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Waters from $330.00 to $345.00 and gave the stock a “neutral” rating in a research note on Wednesday, May 6th. Three investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Waters presently has a consensus rating of “Moderate Buy” and an average target price of $396.68.

Waters Profile

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.